rabeprazole has been researched along with Postoperative Complications in 8 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Postoperative Complications: Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artificial gastric ulcers." | 9.30 | Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. ( Baik, GH; Bang, CS; Choi, MH; Jang, HJ; Kae, SH; Kim, HY; Park, SW; Seo, SI; Shin, SP; Shin, WG; Yang, YJ, 2019) |
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 9.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| "According to this trial, ilaprazole and rabeprazole showed no significant difference in the healing of artificial gastric ulcers." | 5.30 | Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study. ( Baik, GH; Bang, CS; Choi, MH; Jang, HJ; Kae, SH; Kim, HY; Park, SW; Seo, SI; Shin, SP; Shin, WG; Yang, YJ, 2019) |
| "In this prospective, randomized, multicenter, open-label, and comparative study, patients who had undergone ESD for EGC or gastric adenoma were randomized into groups receiving either rabeprazole monotherapy (10 mg/day, n=64) or a combination of rabeprazole plus rebamipide (300 mg/day, n=66)." | 5.22 | Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy. ( Akahoshi, K; Akiho, H; Aso, A; Harada, N; Iboshi, Y; Ihara, E; Iwasa, T; Nakamura, K; Nakamura, N; Ochiai, T; Ogino, H; Takayanagi, R, 2016) |
| "Vonoprazan, a potassium-competitive acid blocker, is expected to improve the healing of endoscopic submucosal dissection (ESD)-induced gastric ulcers compared with proton pump inhibitors (PPIs)." | 5.22 | Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. ( Hasui, T; Inaba, T; Ishida, M; Ishikawa, S; Iwamuro, M; Izumikawa, K; Kagawa, T; Kuraoka, S; Matsuura, M; Sakakihara, I; Sasaki, K; Takahashi, S; Tanaka, S; Wato, M; Yamamoto, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamasaki, A | 1 |
| Yoshio, T | 1 |
| Muramatsu, Y | 1 |
| Horiuchi, Y | 1 |
| Ishiyama, A | 1 |
| Hirasawa, T | 1 |
| Tsuchida, T | 1 |
| Sasaki, Y | 1 |
| Fujisaki, J | 1 |
| Bang, CS | 1 |
| Shin, WG | 1 |
| Seo, SI | 1 |
| Choi, MH | 1 |
| Jang, HJ | 1 |
| Park, SW | 1 |
| Kae, SH | 1 |
| Yang, YJ | 1 |
| Shin, SP | 1 |
| Baik, GH | 1 |
| Kim, HY | 1 |
| Nakamura, K | 1 |
| Ihara, E | 1 |
| Akiho, H | 1 |
| Akahoshi, K | 1 |
| Harada, N | 1 |
| Ochiai, T | 1 |
| Nakamura, N | 1 |
| Ogino, H | 1 |
| Iwasa, T | 1 |
| Aso, A | 1 |
| Iboshi, Y | 1 |
| Takayanagi, R | 1 |
| Kagawa, T | 1 |
| Iwamuro, M | 1 |
| Ishikawa, S | 1 |
| Ishida, M | 1 |
| Kuraoka, S | 1 |
| Sasaki, K | 1 |
| Sakakihara, I | 1 |
| Izumikawa, K | 1 |
| Yamamoto, K | 1 |
| Takahashi, S | 2 |
| Tanaka, S | 1 |
| Matsuura, M | 1 |
| Hasui, T | 1 |
| Wato, M | 1 |
| Inaba, T | 1 |
| Yasu, T | 1 |
| Konuma, T | 1 |
| Kato, S | 1 |
| Kurokawa, Y | 1 |
| Tojo, A | 1 |
| Hata, M | 1 |
| Shiono, M | 1 |
| Sekino, H | 1 |
| Furukawa, H | 1 |
| Sezai, A | 1 |
| Iida, M | 1 |
| Yoshitake, I | 1 |
| Hattori, T | 1 |
| Wakui, S | 1 |
| Soeda, M | 1 |
| Taoka, M | 1 |
| Negishi, N | 1 |
| Sezai, Y | 1 |
| Uedo, N | 1 |
| Takeuchi, Y | 1 |
| Yamada, T | 1 |
| Ishihara, R | 1 |
| Ogiyama, H | 1 |
| Yamamoto, S | 2 |
| Kato, M | 1 |
| Tatsumi, K | 1 |
| Masuda, E | 1 |
| Tamai, C | 1 |
| Higashino, K | 1 |
| Iishi, H | 1 |
| Tatsuta, M | 1 |
| Tanaka, K | 1 |
| Toyoda, H | 1 |
| Hamada, Y | 1 |
| Aoki, M | 1 |
| Kosaka, R | 1 |
| Noda, T | 1 |
| Katsurahara, M | 1 |
| Nakamura, M | 1 |
| Ninomiya, K | 1 |
| Inoue, H | 1 |
| Imoto, I | 1 |
| Takei, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer.[NCT02638584] | Phase 4 | 176 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm[NCT02005809] | Phase 3 | 268 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for rabeprazole and Postoperative Complications
| Article | Year |
|---|---|
Effect of ilaprazole on the healing of endoscopic submucosal dissection-induced gastric ulcer: randomized-controlled, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Endoscopic Mucosal Resection; Fema | 2019 |
Limited Effect of Rebamipide in Addition to Proton Pump Inhibitor (PPI) in the Treatment of Post-Endoscopic Submucosal Dissection Gastric Ulcers: A Randomized Controlled Trial Comparing PPI Plus Rebamipide Combination Therapy with PPI Monotherapy.
Topics: Adenoma; Aged; Alanine; Anti-Ulcer Agents; Drug Therapy, Combination; Endoscopic Mucosal Resection; | 2016 |
Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.
Topics: Adenoma; Aged; Aged, 80 and over; Endoscopic Mucosal Resection; Female; Gastrointestinal Hemorrhage; | 2016 |
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu | 2005 |
Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cimetidi | 2007 |
3 other studies available for rabeprazole and Postoperative Complications
| Article | Year |
|---|---|
Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Drug Substitution; Endoscopic Mucosal R | 2018 |
Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Body Weight; Bone Marrow Transplan | 2016 |
A relapse case of acute necrotizing esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Aged; Biopsy; Esophagitis; Esophagoscopy; Es | 2007 |